Cargando…
A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with around 9% of patients surviving >5 years. Asymptomatic in its initial stages, PDAC is mostly diagnosed late, when already a locally advanced or metastatic disease, as there are no useful biomarkers for detec...
Autores principales: | Debernardi, Silvana, O’Brien, Harrison, Algahmdi, Asma S., Malats, Nuria, Stewart, Grant D., Plješa-Ercegovac, Marija, Costello, Eithne, Greenhalf, William, Saad, Amina, Roberts, Rhiannon, Ney, Alexander, Pereira, Stephen P., Kocher, Hemant M., Duffy, Stephen, Blyuss, Oleg, Crnogorac-Jurcevic, Tatjana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758047/ https://www.ncbi.nlm.nih.gov/pubmed/33301466 http://dx.doi.org/10.1371/journal.pmed.1003489 |
Ejemplares similares
-
Response to the comment on “Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients”
por: Blyuss, Oleg, et al.
Publicado: (2020) -
Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients
por: Blyuss, Oleg, et al.
Publicado: (2019) -
Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’
por: De Marco, Margot, et al.
Publicado: (2020) -
Demographic, clinical, and pathological features of early onset pancreatic cancer patients
por: Ntala, Chara, et al.
Publicado: (2018) -
Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis
por: Debernardi, Silvana, et al.
Publicado: (2022)